Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
65.01
+2.95 (4.75%)
At close: Jan 7, 2026, 4:00 PM EST
65.07
+0.06 (0.09%)
After-hours: Jan 7, 2026, 7:56 PM EST
Arcellx Employees
Arcellx had 163 employees as of December 31, 2024. The number of employees increased by 33 or 25.38% compared to the previous year.
Employees
163
Change (1Y)
33
Growth (1Y)
25.38%
Revenue / Employee
$220,233
Profits / Employee
-$1,336,828
Market Cap
3.76B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 163 | 33 | 25.38% |
| Dec 31, 2023 | 130 | 32 | 32.65% |
| Dec 31, 2022 | 98 | 20 | 25.64% |
| Dec 31, 2021 | 78 | 47 | 151.61% |
| Dec 31, 2019 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACLX News
- 21 days ago - Arcellx: Funded Into 2028 With Strong Clinical Data - Seeking Alpha
- 4 weeks ago - Cancer Study Buoys These Small Biotechs - Barrons
- 4 weeks ago - Why Is Arcellx Stock Surging Today? - Benzinga
- 4 weeks ago - Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript - Seeking Alpha
- 4 weeks ago - Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - Business Wire
- 7 weeks ago - Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition - Business Wire
- 2 months ago - Arcellx Provides Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition - Business Wire